NCT05992298 Feasibility Testing of 7-Tesla Magnetic Resonance Imaging
| NCT ID | NCT05992298 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Reto Sutter, MD |
| Condition | Magnetic Resonance Imaging |
| Study Type | INTERVENTIONAL |
| Enrollment | 780 participants |
| Start Date | 2023-08-07 |
| Primary Completion | 2028-02-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 780 participants in total. It began in 2023-08-07 with a primary completion date of 2028-02-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the current project is to explore and develop the technical feasibility of non-invasive imaging of the human musculoskeletal system and head with the first 7T MR scanner with a CE mark to identify areas where the higher field promises significant benefits in qualitative image quality. For a subset of the planned exams, state-of-the art 7T or 3T images will be used as standard of reference to comparatively gauge the qualitative image quality of the investigational 7T images.
Eligibility Criteria
Inclusion Criteria: * Consent to undergo a 7T (and, if appropriate a comparative 3T) MRI exam. * For some of the consistent small series: presence of a specific condition of the musculoskeletal system or of the head. This can include traumatic or degenerative changes, e.g., of tendons, cartilage, muscle, peripheral nerves, ligaments, and bones, or in the brain, as well as focal lesions, e.g., tumors. Exclusion Criteria: * Contraindications to undergo a MRI examination at a field strength of 7 Tesla or at 3 Tesla. * Irregular anatomy and/or tissue properties * Inability to consent - for any reason. * Body mass above 200 kg. * Body mass below 30 kg. * Women: pregnancy. * Age below 18. * Known or suspected non-compliance, drug or alcohol abuse. * Inability to follow the procedures of the study.
Contact & Investigator
Reto Sutter, Prof.
PRINCIPAL INVESTIGATOR
Balgrist University Hospital
Frequently Asked Questions
Who can join the NCT05992298 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Magnetic Resonance Imaging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05992298 currently recruiting?
Yes, NCT05992298 is actively recruiting participants. Contact the research team at reto.sutter@balgrist.ch for enrollment information.
Where is the NCT05992298 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT05992298 clinical trial?
NCT05992298 is sponsored by Reto Sutter, MD. The principal investigator is Reto Sutter, Prof. at Balgrist University Hospital. The trial plans to enroll 780 participants.